Central Serous Chorioretinopathy Pipeline Analysis & Clinical Trials, 2025, Delveinsight Targeted Therapy Technologies, Corcept Therapeutics, Bayer, And Others

(MENAFN- GetNews)


"Central serous chorioretinopathy Pipeline"DelveInsight's,“Central Serous Chorioretinopathy – Pipeline Insight, 2025,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Central Serous Chorioretinopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

DelveInsight reports that the Central Serous Chorioretinopathy (CSC) pipeline includes 3+ key companies actively engaged in developing 3+ therapeutic candidates for CSC treatment.

Central serous chorioretinopathy Overview:

Central Serous Chorioretinopathy (CSC) is an eye disorder characterized by fluid accumulation beneath the retina, causing serous detachment and visual disturbances. It most often affects young to middle-aged adults, with men being more commonly impacted, though the exact reason remains unclear. While many cases resolve spontaneously with temporary vision loss, CSC can become chronic or recurrent in some patients.

Diagnosis typically involves a comprehensive dilated eye exam, optical coherence tomography (OCT) for detailed retinal imaging, and sometimes fluorescein angiography, which uses dye to detect retinal leakage. Treatment options for chronic cases may include thermal laser therapy, photodynamic therapy (a“cold laser” technique targeting fluid leaks), oral medications, and intraocular injections. Early detection is crucial, as timely treatment can significantly improve outcomes and reduce the risk of permanent vision loss.

Download our report @

"Central serous chorioretinopathy Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Central serous chorioretinopathy Therapeutics Market.

Key Takeaways from the Central serous chorioretinopathy Pipeline Report

• DelveInsight's report on the Central Serous Chorioretinopathy (CSC) pipeline highlights an active landscape with 3+ companies developing 3+ therapeutic candidates for CSC treatment.

• Findings from the 2020 VICI randomized controlled trial showed that eplerenone offered no significant benefit over placebo in improving visual outcomes for chronic CSC.

• Leading companies such as Targeted Therapy Technologies, Corcept Therapeutics, Bayer, and others are advancing new treatment options to enhance the therapeutic landscape.

• Promising pipeline candidates include Aflibercept and additional emerging therapies.

Central serous chorioretinopathy Pipeline Analysis

The Central serous chorioretinopathy pipeline insights report 2025, provides insights into:

• Provides comprehensive insights into key companies developing therapies in the Central serous chorioretinopathy Market.

• Categorizes Central serous chorioretinopathy therapeutic companies by development stage: early, mid, and late-stage.

• Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

• Reviews emerging Central serous chorioretinopathy drugs under development based on:

  • Stage of development

  • Central serous chorioretinopathy Route of administration

  • Target receptor

  • Monotherapy vs. combination therapy

  • Central serous chorioretinopathy Mechanism of action

  • Molecular type

• Offers detailed analysis of:

  • Company-to-company and company-academia collaborations

  • Central serous chorioretinopathy Licensing agreements

  • Funding and investment activities supporting future Central serous chorioretinopathy market advancement.

Request for a sample report @

Central serous chorioretinopathy Emerging Drugs

• Aflibercept: Bayer

Aflibercept is a therapeutic agent that blocks both placental growth factor (PlGF) and vascular endothelial growth factor A (VEGF-A). Originally developed by Regeneron Pharmaceuticals, it was later licensed to Bayer and Sanofi. The drug is currently being evaluated in Phase II clinical trials.

Central serous chorioretinopathy Companies

More than three leading companies are developing therapies for Central Serous Chorioretinopathy (CSC), with Bayer advancing the most progressed candidate, which is currently in Phase II development.

DelveInsight's report covers around 3+ products under different phases of Central serous chorioretinopathy clinical trials like

• Central serous chorioretinopathy Late stage Therapies (Phase III)

• Central serous chorioretinopathy Mid-stage Therapies (Phase II)

• Central serous chorioretinopathy Early-stage Therapies (Phase I)

• Central serous chorioretinopathy Pre-clinical and Central serous chorioretinopathy Discovery stage Therapies

• Central serous chorioretinopathy Discontinued & Inactive Therapies

Central serous chorioretinopathy pipeline report provides the Central serous chorioretinopathy therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

Central serous chorioretinopathy Products have been categorized under various Molecule types such as

• Monoclonal antibody

• Small molecule

• Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Central serous chorioretinopathy Therapies and Key Central serous chorioretinopathy Companies: Central serous chorioretinopathy Clinical Trials and recent advancements

Central serous chorioretinopathy Pipeline Therapeutic Assessment

. Central serous chorioretinopathy Assessment by Product Type

. Central serous chorioretinopathy By Stage

. Central serous chorioretinopathy Assessment by Route of Administration

. Central serous chorioretinopathy Assessment by Molecule Type

Download Central serous chorioretinopathy Sample report to know in detail about the Central serous chorioretinopathy treatment market @ Central serous chorioretinopathy Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Central serous chorioretinopathy Current Treatment Patterns

4. Central serous chorioretinopathy - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Central serous chorioretinopathy Late-Stage Products (Phase-III)

7. Central serous chorioretinopathy Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Central serous chorioretinopathy Discontinued Products

13. Central serous chorioretinopathy Product Profiles

14. Central serous chorioretinopathy Key Companies

15. Central serous chorioretinopathy Key Products

16. Dormant and Discontinued Products

17. Central serous chorioretinopathy Unmet Needs

18. Central serous chorioretinopathy Future Perspectives

19. Central serous chorioretinopathy Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Central serous chorioretinopathy Pipeline Reports Offerings

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

MENAFN10092025003238003268ID1110045980